Bioxytran (BIXT) Stock Price, News & Analysis

Company Overview

Bioxytran, Inc., a clinical stage pharmaceutical company, focuses on the development, manufacture, and commercialization of therapeutic drugs to address hypoxia in humans. The company's lead drug candidate is BXT-25, an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer for use in the treatment of hypoxic conditions in the brain resulting from stroke, and hypoxic conditions in wounds to prevent necrosis and to promote healing. It is also developing ProLectin-Rx, a polysaccharide derived from pectin that binds to, and blocks the activity of galectin-1, a type of galectin for treatment of mild to moderate cases of Covid-19. The company was founded in 2008 and is headquartered in Needham, Massachusetts.

Key Stats

• Today's Range: $0.15 to $0.17
• 50-Day Range: $0.07 to $0.19
• 52-Week Range: $0.06 to $0.23
• Volume: 4,924 shs
• Average Volume: 260,853 shs
• Market Capitalization: $16.24 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

BIXT Stock Analysis - Frequently Asked Questions

How have BIXT shares performed this year?

Bioxytran's stock was trading at $0.0899 at the beginning of the year. Since then, BIXT shares have increased by 80.3% and is now trading at $0.1621.
View the best growth stocks for 2025 here.

How were Bioxytran's earnings last quarter?

Bioxytran, Inc. (OTCMKTS:BIXT) issued its quarterly earnings results on Thursday, April, 3rd. The company reported ($0.01) earnings per share for the quarter.

How do I buy shares of Bioxytran?

Shares of BIXT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Bioxytran own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Bioxytran investors own include AMC Entertainment (AMC), Armata Pharmaceuticals (ARMP), bluebird bio (BLUE), Esports Entertainment Group (GMBL), Genius Group (GNS), Novavax (NVAX) and Karora Resources Inc. (RNX.TO) (RNX).

Company Calendar

• Last Earnings: 4/03/2025
• Today: 4/26/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:BIXT
• CIK: 1445815
• Web: www.bioxytraninc.com
• Phone: (617) 454-1199
• Fax: N/A
• Employees: 2
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($0.01)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-4,470,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -2,100.34%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.03
• Quick Ratio: 0.03

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.02) per share
• Price / Book: -8.11

Miscellaneous

• Outstanding Shares: 100,173,000
• Free Float: 26,440,000
• Market Cap: $16.24 million
• Optionable: Not Optionable
• Beta: 0.98